Gene Network Sciences Awarded Patent Covering REFSTM Platform
| Contact: |  |
Thomas Neyarapally Gene Network Sciences (617) 494-0492 tneyarapally@gnsbiotech.com |
Cambridge, MA — May 5, 2009 — Gene Network Sciences, Inc. (GNS) today announced that it has been awarded U.S. Patent No. 7,512,497, entitled "Systems and Methods for Inferring Biological Networks." The patent covers GNS's core model learning and simulation platform, REFSTM (Reverse Engineering and Forward Simulation).
GNS has deployed the REFSTM platform in several collaborations with pharmaceutical and biotechnology companies and academic and clinical institutions in diseases areas such as oncology, rheumatoid arthritis, cardiovascular and metabolic disease, and Alzheimer's disease. The REFSTM platform, which is run on supercomputers, enables the rapid extraction of actionable, patient-specific knowledge directly from experimental and clinical data.
"We have now extended our patent portfolio beyond our previous issued patents covering an ultra-efficient language to model known biology and the simulation of known pathways, to the fully data-driven inference and simulation of novel biology," said Tom Neyarapally, Senior Vice President of Corporate Development for GNS. "GNS now has broad intellectual property coverage across our modeling and simulation activities."
GNS has several other pending patent applications addressing the REFSTM platform and its use in areas of application in biological systems and areas outside of biology such as quantitative finance, online advertising, and natural resource exploration, as well as applications covering drug targets, biomarkers, and diagnostic markers discovered using the REFSTM platform.
About Gene Network Sciences
Founded in 2000, Gene Network Sciences ( http://www.gnsbiotech.com ) is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data. Based in Cambridge, Massachusetts, and Ithaca, New York, GNS uses its REFSTM (reverse engineering and forward simulation) technology in pharmaceutical and healthcare settings to rapidly turn combinations of genetic, genomic, and clinical measurements into models of disease progression and drug response. These models are then simulated to discover both new targets for drug intervention and genetic markers of drug response that allow patients who will respond to a given drug treatment to be matched to a particular clinical trial and treatment option. By discovering how and why specific sets of genes and drug candidates impact human biology, GNS technology enables the rapid development of breakthrough drug and diagnostic products and the matching of patients to the optimal therapy.
# # #